TY - JOUR
T1 - Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress inpatients with type 2 diabetes mellitus
AU - Kelly, Aaron S.
AU - Thelen, Andrea M.
AU - Kaiser, Daniel R.
AU - Gonzalez-Campoy, J. Michael
AU - Bank, Alan J.
PY - 2007
Y1 - 2007
N2 - We compared the vascular effects of rosiglitazone versus glyburide and evaluated asymmetric dimethylarginine (ADMA) and oxidative stress as potential mechanisms associated with changes in vascular health in patients with type 2 diabetes mellitus (T2DM). Patients were randomized to 6 months of either rosiglitazone (n = 20) or glyburide (n = 16) in addition to metformin. The following variables were measured pre- and post-treatment: glucose, insulin, homeostasis model assessment (HOMA), hemoglobin A1c (HbA1c), C-peptide, blood pressure, lipids, C-reactive protein (CRP), ADMA, 8-isoprostane, oxidized LDL cholesterol, brachial artery flow-mediated dilation (FMD), endothelium-independent dilation (EID), and brachial and carotid artery stiffness. Rosiglitazone and glyburide treatment resulted in significant and equivalent decreases in glucose (p<0.0001) and HbA1c (p<0.0001), with a trend toward decreased HOMA (p=0.09). Rosiglitazone significantly decreased C-peptide (p < 0.01) with a strong trend toward decreased fasting insulin (p=0.05). Rosiglitazone reduced CRP compared with glyburide (p=0.001), but no differences were observed between groups for ADMA or the markers of oxidative stress. Rosiglitazone significantly improved FMD (p < 0.05) with trends toward improvements in carotid artery distension (p = 0.099) and distensibility (p = 0.078). In conclusion, compared with glyburide, rosiglitazone improves endothelial function and CRP in patients with T2DM. These improvements are not associated with reductions in ADMA or markers of oxidative stress.
AB - We compared the vascular effects of rosiglitazone versus glyburide and evaluated asymmetric dimethylarginine (ADMA) and oxidative stress as potential mechanisms associated with changes in vascular health in patients with type 2 diabetes mellitus (T2DM). Patients were randomized to 6 months of either rosiglitazone (n = 20) or glyburide (n = 16) in addition to metformin. The following variables were measured pre- and post-treatment: glucose, insulin, homeostasis model assessment (HOMA), hemoglobin A1c (HbA1c), C-peptide, blood pressure, lipids, C-reactive protein (CRP), ADMA, 8-isoprostane, oxidized LDL cholesterol, brachial artery flow-mediated dilation (FMD), endothelium-independent dilation (EID), and brachial and carotid artery stiffness. Rosiglitazone and glyburide treatment resulted in significant and equivalent decreases in glucose (p<0.0001) and HbA1c (p<0.0001), with a trend toward decreased HOMA (p=0.09). Rosiglitazone significantly decreased C-peptide (p < 0.01) with a strong trend toward decreased fasting insulin (p=0.05). Rosiglitazone reduced CRP compared with glyburide (p=0.001), but no differences were observed between groups for ADMA or the markers of oxidative stress. Rosiglitazone significantly improved FMD (p < 0.05) with trends toward improvements in carotid artery distension (p = 0.099) and distensibility (p = 0.078). In conclusion, compared with glyburide, rosiglitazone improves endothelial function and CRP in patients with T2DM. These improvements are not associated with reductions in ADMA or markers of oxidative stress.
KW - Asymmetric dimethylarginine
KW - Endothelial function
KW - Oxidative stress
KW - Rosiglitazone
KW - Type 2 diabetes mellitus
UR - http://www.scopus.com/inward/record.url?scp=38449122045&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=38449122045&partnerID=8YFLogxK
U2 - 10.1177/1358863X07084200
DO - 10.1177/1358863X07084200
M3 - Article
C2 - 18048467
AN - SCOPUS:38449122045
SN - 1358-863X
VL - 12
SP - 311
EP - 318
JO - Vascular Medicine
JF - Vascular Medicine
IS - 4
ER -